Editorial
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastrointest Pathophysiol. Feb 15, 2012; 3(1): 1-9
Published online Feb 15, 2012. doi: 10.4291/wjgp.v3.i1.1
Table 2 Major natural compounds targeting Wnt/β-catenin pathway undergoing clinical trials for the treatment of colon cancer
CategoryCompoundTargetMechanismClinical trials
identification No.
VitaminsRetinoids/vitamin-ABeta-cateninCompete with TCFs, production of inhibitory protein-disabled-2NCT00270647, NCT00712647
Vitamin-DBeta-cateninProduction of inhibitory proteins-dickkopf-1 and 4NCT00208793, NCT00870961, NCT01198548, NCT00399607, NCT01150877, NCT00585637
Vitamin-EUnknownUnknownNCT00706121, NCT00270647
PyridoxineUnknownUnknownNCT00559858
PolyphenolsQuercetinWnt/beta-cateninUnknownNCT00003365
Epigallocatechin-3-gallate from green teaWnt/beta-cateninPlieotropicNCT01239095, NCT00718094
CurcuminWnt/beta-cateninPlieotropicNCT00365209, NCT00295035, NCT00027495, NCT00973869, NCT00745134, NCT00118989, NCT00927485, NCT00641147
ResveratrolWnt/beta-cateninUnknownNCT00256334, NCT00578396, NCT00433576, NCT00920803
Dictyostelium discoidemWnt/beta-cateninActivation of GSK-3beta by differentiation inducing factors-1,3No current trails
LipidsOmega 3 fatty acids and n-3 polyunsaturated fatty acidsMitochondrial membrane of tumor cellsEnhanced reactive oxygen species generation and decreased cell anti-oxidant capacity leading to apoptosis in tumor cellsNCT01127867, NCT00145015, NCT01218841, NCT00432913, NCT00488904, NCT00168987, NCT00510692, NCT01070355, NCT01048463